Pricing Log in Create free account
Friday 6 November 2026 Export IMVT’s income statement to Excel — free account

Immunovant, Inc.

IMVT Healthcare Biotechnology

EPS
−5.63%
Free cash flow
−5.96%

Quarter to June 2026, against a year earlier

30.53 2.14 +7.54%
Market cap
$5.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Immunovant, Inc. (IMVT) valuation and DCF model

What the price implies · reverse DCF

Immunovant, Inc. is not valued here: free cash flow is negative and there is no revenue to read the price through.

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Biotechnology).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/B 8.53× 8.53× 8.53× 0% above 2.05× 316% above

IMVT trades at 8.53× P/B, against a 10-year average of 8.53× (range 8.53×–8.53×). Re-rating to the average implies $30.53 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.